Very early researchLooking for participantsNCT06031727
What this trial is testing
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)
HuidaGene Therapeutics Co., Ltd. 12